ChromaDex Corporation (CDXC)
NASDAQ: CDXC · Real-Time Price · USD
5.49
+0.08 (1.48%)
Dec 20, 2024, 4:00 PM EST - Market closed
ChromaDex Revenue
ChromaDex had revenue of $25.58M in the quarter ending September 30, 2024, with 31.21% growth. This brings the company's revenue in the last twelve months to $91.67M, up 9.95% year-over-year. In the year 2023, ChromaDex had annual revenue of $83.57M with 15.99% growth.
Revenue (ttm)
$91.67M
Revenue Growth
+9.95%
P/S Ratio
4.52
Revenue / Employee
$864,792
Employees
106
Market Cap
420.26M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 83.57M | 11.52M | 15.99% |
Dec 31, 2022 | 72.05M | 4.60M | 6.82% |
Dec 31, 2021 | 67.45M | 8.19M | 13.82% |
Dec 31, 2020 | 59.26M | 12.97M | 28.01% |
Dec 31, 2019 | 46.29M | 14.73M | 46.69% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 30, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Jan 2, 2016 | Pro | Pro | Pro |
Jan 3, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Village Super Market | 2.26B |
Nu Skin Enterprises | 1.78B |
Calavo Growers | 1.01B |
Oatly | 813.47M |
SNDL Inc. | 674.50M |
American Public Education | 613.25M |
Yatsen Holding | 472.96M |
BrasilAgro - Companhia Brasileira de Propriedades Agrícolas | 216.81M |
CDXC News
- 19 days ago - ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category - Business Wire
- 5 weeks ago - ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement - Business Wire
- 6 weeks ago - ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide - Business Wire
- 7 weeks ago - ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - ChromaDex Corporation Reports Third Quarter 2024 Financial Results - Business Wire
- 7 weeks ago - ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024 - Business Wire
- 2 months ago - ChromaDex to Participate in the 17th Annual LD Micro Main Event - Business Wire
- 2 months ago - Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) - Business Wire